Treatment of immunocompromised conditions
AssigneeThe University of Queensland
InventorsJean-Pierre Levesque, Ingrid Winkler
Life of this patent
Estimating the term…
Abstract
This invention discloses the use of an E-selectin antagonist in methods and compositions for treating or preventing immunocompromised conditions resulting from medical treatment. The present invention is particular useful for prophylaxis and/or treatment of hematopoietic disorders including neutropenia, agranulocytosis, anemia and thrombocytopenia in individuals receiving or proposed to receive treatments that target rapidly dividing cells or that disrupt the cell cycle or cell division.
Claims51
A method for treating an immunocompromised condition in a subject, which condition results from a medical treatment comprising chemotherapy or radiation therapy, the method comprising administering to the subject an E-selectin antagonist in an effective amount to treat the immunocompromised condition, wherein the subject is not exposed to an ancillary treatment that comprises transplantation of hematopoietic stem cells (HSC), other than autologous HSC, and wherein the E-selectin antagonist binds to E-selectin.
A method for increasing the dose of radiation or chemotherapy administered to a subject undergoing radiation therapy or chemotherapy, the method comprising administering the radiation or chemotherapy to the subject in a dose that ordinarily induces immunocompromising effects, together with an E-selectin antagonist in an effective amount to lessen the immunocompromising effects of the radiation or chemotherapy, wherein the subject is not exposed to an ancillary treatment that comprises transplantation of hematopoietic stem cells (HSC), other than autologous HSC, and wherein the E-selectin antagonist binds to E-selectin.
A method for reducing the immunocompromising side-effects of a medical treatment comprising chemotherapy or radiation therapy, the method comprising administering to the subject an E-selectin antagonist in an effective amount to reduce the immunocompromising side-effects of the medical treatment, wherein the subject is not exposed to an ancillary treatment that comprises transplantation of hematopoietic stem cells (HSC), other than autologous HSC, and wherein the E-selectin antagonist binds to E-selectin.
Dependencies are inferred from the claim text.